Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Buy” by Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been given an average rating of “Buy” by the eight research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $32.29.

A number of research firms recently commented on DAWN. Bank of America lowered their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. dropped their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Wedbush reissued an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, March 25th.

Day One Biopharmaceuticals Stock Down 4.0 %

Shares of NASDAQ DAWN opened at $7.61 on Wednesday. The business’s 50 day moving average price is $10.41 and its two-hundred day moving average price is $12.51. The company has a market cap of $771.31 million, a PE ratio of -7.39 and a beta of -1.38. Day One Biopharmaceuticals has a twelve month low of $7.52 and a twelve month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. As a group, research analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 4,646 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. The trade was a 10.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeremy Bender sold 12,048 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company’s stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,064 shares of company stock valued at $251,925. 8.40% of the stock is currently owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter valued at $866,000. Charles Schwab Investment Management Inc. boosted its stake in Day One Biopharmaceuticals by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock valued at $7,069,000 after purchasing an additional 64,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Day One Biopharmaceuticals by 90.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock worth $1,535,000 after purchasing an additional 57,601 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Day One Biopharmaceuticals by 10.5% in the third quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock worth $19,961,000 after purchasing an additional 136,458 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in shares of Day One Biopharmaceuticals in the third quarter valued at approximately $725,000. 87.95% of the stock is owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.